Immune System, Inflammation and Autoantigens in wAMD: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Sreeraj Kuruppilakath Manikandan
,
Ann Logan
,
Marc Cerrada-Gimenez
,
Laurence Fitzhenry
,
Lee Coffey
,
Simon Kaja
,
Sweta Rani

Wet age-related macular degeneration (wAMD) is a chronic inflammation-associated neurodegenerative disease affecting the posterior part of the eye in the aging population. Aging results in the reduced functionality of cells and tissues, including the cells of the retina. Initiators of a chronic inflammatory and pathologic state in wAMD may be a result of the accumulation of inevitable metabolic injuries associated with the maintenance of tissue homeostasis from a young age to over 50. Apart from this, risk factors like smoking, genetic predisposition, and failure to repair the injuries that occur, alongside attempts to rescue the hypoxic outer retina may also contribute to the pathogenesis. Aging of the immune system (immunosenescence) and a compromised outer blood retinal barrier (BRB) result in the exposure of the privileged milieu of the retina to the systemic immune system, further increasing the severity of the disease. 

  • injury
  • autoantigens
  • protective autoimmunity
  • inflammation
  • aging

1. Introduction

One of the leading causes of vision loss in older people is age-related macular degeneration (AMD). It is projected that the number of people suffering from AMD will reach 288 million by the year 2040 [1][2][3]. The increasing number of elderly people diagnosed with AMD is a socioeconomic challenge and a challenge to healthcare, as it affects quality of life and independence in this patient population. AMD affects mainly the choroid (including the choriocapillaris), Bruch’s membrane (BM), retinal pigment epithelium (RPE), and photoreceptors (PR) located central to the neural retina (Figure 1). The progressive nature of the disease often leads to a sequence of pathological stages, beginning with early-stage dry AMD (dAMD) pigmentary changes, accumulation of metabolic waste/deposits, and death of PR and RPE, which can progress to chronic disease states such as wAMD, geographic atrophy (GA), or subretinal fibrosis [4][5][6][7][8][9][10][11][12][13].
Life 13 02236 g001
Figure 1. Schematic representation of the retinal structure. Showing an enlarged view of the neurosensory retina, where the central area is called the macular region, which is mostly composed of cone photoreceptor (PR) cells. The loss of macula PR cells affects the central vision since the cones are responsible for activities dependent on visual acuity like reading, driving, writing, and color recognition. Image created in Biorender.com.
Currently, there is no cure for early or dAMD and associated conditions; however, recently, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) administered intravitreally were approved by the FDA for the treatment of GA [14][15]. The mainstay therapy for wAMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. Other potential therapeutic targets could be placental growth factor (PIGF) and angiopoietin 2, and both play a central role in neovascularization [16][17][18][19][20][21][22]. Irrespective of the available treatment options, there is a significant treatment burden associated with intravitreal therapy (IVT), including the need for frequent injections, variable vision outcomes, and of course the risks associated with injections, such as retinal detachment, infective endophthalmitis, and drug-induced uveitis [23][24].
The major risk factors of wAMD include increasing age combined with lifestyle risk factors such as the Western diet and smoking in individuals with genetic predispositions such as polymorphisms of the complement system, as revealed by genome-wide association studies (GWAS) [25]. The early pathological sign of AMD is drusen and the increase in the size of RPE drusen deposits in the basal and linear areas of RPE is an early indicator of AMD development risk [26][27][28][29]. Impaired autophagy and metabolic clearance by the RPE cells contribute to the development of drusen. Local immune cells are the initial responders to any infection or injury in the retina. When the cycle of retinal injury and repair continues unabated, the resident immune cells require support from the systemic immune cells in a similar manner to that reported in neurodegenerative diseases by Schwartz and Shechter in 2010 [30]. If the retinal injuries/damage become persistent such that the resident immune cells become exhausted and sustained systemic support is required, this eventually may result in a chronic inflammatory response [31][32].

2. Inflammation, Immune Response, and Repair in Wet AMD

Inflammation is a natural response that is initiated against a stimulus potentially dangerous to cells, and its purpose is the protection of cells, tissues, or organs from the spread of the incipient infection/damage [33][34]. It involves a coordinated cascade of events like vasoconstriction, vasodilation, release of histamines/kinins/chemokines, migration of immune cells, endothelial attachment, extravasation, chemotaxis, phagocytosis, and elimination of the causative organism/cell/agent. The response subsides in time in a period called the resolution of inflammation. The subsidence of the inflammatory process then leads to the restoration of affected/injured tissue structure and function through repair or regeneration [34]. The resolution of inflammation is of paramount importance when it comes to the restoration of tissue structure and function, and although sustained inflammation is not usually the primary causative factor of chronic disease, its significance to disease evolution cannot be ruled out [34]. The transition of a pro-inflammatory to an anti-inflammatory (wound healing) state is a complex switching process which is dependent on the timely action of key molecules associated with the process [31][33]. For example, the switching of prostaglandin stimulation in the pro-inflammatory state to lipoxin stimulation in the anti-inflammatory state is crucial for the resolution of inflammation [31]. The same cytokines involved in initiating a pro-inflammatory milieu may later switch to an anti-inflammatory influence, acting as a double-edged sword in the process of inflammation resolution. Importantly, the autocrine loop of immune cells, regulatory events, cell signaling, and biochemical events all need to maintain homeostatic function to effectively carry out the events leading to tissue restoration.
Inflammation is a crucial factor in the pathogenesis of AMD [4][23][29][32][35]. Key elements of the inflammatory response are induced when the pattern recognition receptors (PRRs) face perceived danger. The immune system is alerted by endogenous factors called alarmins, which communicate with the immune cells to induce immune responses. These alarm responses are detected by toll-like receptors (TLRs), which also bind to exogenous antigens called pathogen-associated molecular patterns (PAMPs) to elicit a cascade of pro-inflammatory responses [36]. AMD pathogenesis is generally regarded as a possible interplay of genetic factors, hypoxia, and metabolic irregularities. For example, the accumulation of oxidative stressors in tissues that occurs as part of aging activates the PRRs, initiating pro-inflammatory responses as a secondary response to accumulating tissue damage [32]. The initial low levels of tissue stress induce para-inflammation, an intermediate state that is contrary to the basal homeostatic state, rather than a classic inflammatory response [31]. Para-inflammation is the small-scale supply of immune cells to assist the resolution of the stressful situation and to restore functionality and homeostasis in the affected tissue when a local immune response alone cannot handle the situation [32]. Para-inflammation responses are dysregulated [35] when local immune cells are exhausted [32] and thereby contribute to the development of chronic inflammatory conditions associated with many progressive diseases [31].
Prior to disease initiation, para-inflammatory responses support tissue homeostasis through a small-scale supply of immune cells to the damage or injured sites [31][32]. As tissue injuries/damage accumulate over time, these para-inflammatory responses eventually convert to a chronic inflammatory state, as a more robust inflammatory response is initiated in the damaged sites. At some stage, the retina may secrete autoantigens as a mediator for communicating with the adaptive immune system. When this communication between the autoantigen and the adaptive immune system is appropriately controlled, a favorable inflammatory response is initiated; however, detrimental autoreactivity can happen when this control is lost. Many factors can change the course of safe autoreactivity. In a weakened immune system, where autoantigens cannot be processed in a timely manner or provide nutrient perfusion, oxygen, and immune cells to the injured site, this can complicate the timing of events during repair and can elicit a pathogenic state that progressively worsens. The significance of autoantigens present during different stages of the repair process or disease progression requires a deeper exploration as their purpose may not be the same at different stages.
In AMD, the persistence of para-inflammatory states may lead to chronic inflammation and contribute to movement to later stages of the disease [32]. When there is already a chronic inflammatory state existing in tissues, the accumulation of further insults over time could invite additional acute inflammatory responses that drive new adverse tissue responses including soft drusen development, RPE/PR atrophy, and oxidative damage, all acting as antigenic stimuli [8][32][37][38]. A simultaneous occurrence of acute and chronic inflammation with continuous metabolic and oxidative stress can create a persistent hyperinflammatory state culminating in a pathologic state. Dysregulated immune responses will eventually lead to incomplete repair, scar tissue formation, and a failure to restore the functionality of the original tissue, leading to persistent disease states.
Resident retina immune cells, notably microglia, also contribute to the transition from a transient inflammatory state to a persistent disease state. Microglia are activated and migrate to the sub-retinal space during injury. The microglial migration from inner to outer retina is compensated by the recruitment of systemic monocytes, which become macrophages after entering the retina from the circulation [39]. These macrophages, together with the retinal microglia, play a major role in the para-inflammation response, which involves the clearance of the sub-retinal space from debris and restoration of tissue homeostasis [29][31]. Activation of the adaptive immune system is required to recruit immune cells and initiate crosstalk to assist in tissue repair. Crosstalk occurs via the release of autoantigens and antigen presentation to T cells. Here, the adaptive immune system exerts protective effects and aids in repair, in part due to the exquisite specificity that is required to supplement the innate response in mediating and resolving inflammation [40] when resident retinal immune cells have become dysregulated. Differences in the extent of the protective adaptive response may explain which inflammatory environment favors AMD.
This is based on the working hypothesis that AMD progression can be attributed to a persistent local inflammatory state in the retina causing PR and RPE insult. Cell debris and aggregated proteins accumulating in the retina activate the resident microglia to phagocytose these unwanted inclusions. Upon phagocytosing the debris, the microglia secrete pro-inflammatory cytokines and toxic compounds like reactive oxygen species (ROS), in a similar manner to the CNS disease conditions proposed by Schwartz and Shechter [30]. If prolonged/uncontrolled microglial activation exists, the survival of nearby uncompromised cells may become affected by the secretion of these toxic agents and further activation of microglia. Autoantigens may be released by the retinal cells at this stage (something similar to the ‘equilibrium stage’ proposed by Schwartz and Raposo in 2010 and 2014) [30][41] to bring help from the systemic immune system in an attempt to maintain homeostasis. These autoantigens presented to T cells induce an autoimmunity response, which is protective to the injured area [41]. As a part of this T cell response, monocytes are recruited to the retina and differentiate into macrophages displaying a similar morphology to microglia. These monocyte-derived macrophages assist in clearing the debris and suppress microglial activation by secreting anti-inflammatory cytokines and growth factors, so that the inflammatory response moves towards resolution.
The outer retina, where PRs are located, is avascular and receives metabolic support from the choroid. In pathogenic states, the required transport and clearance mechanisms of nutrients and metabolic waste may be interrupted in the retina. RPE, the macrophages and monocytes in the neighboring tissue or the choroid itself start giving signals to develop new blood vessels to supply nutrients and more immune cells to the hypoxic retina. When comparing this mechanism to AMD, it is a normal part of the inflammatory and proliferative stage of wound healing that is clearly represented in wAMD [42][43], and a response which at some point turns pathogenic.
A reason for this may be the result of insufficient inflammation and macrophage trafficking at the injury site required to clean or make the site debris-free for the maturation of angiogenic vessels. For the proper maturation of blood vessels and new tissue formation to occur in disease-compromised tissue, retinal immune cells need to efficiently complete the autocrine loop of recruiting more macrophages to the injury site. Signals from macrophages and RPE stimulate monocytes to differentiate to a dendritic-like phenotype and then migrate to the lymph nodes with the antigens acquired from the injured area where they present them to the adaptive immune system. Such activity requires a robust inflammatory response to recruit monocytes to respond to retinal antigens and interact with the adaptive immune system. An appropriate tissue response is dependent on the further involvement of the adaptive immune system to help and responsibly execute the necessary steps that eventually lead to new tissue formation. This is achieved either by RPE de-differentiation or migration to restore lost cells, or through the differentiation of bone-marrow-derived/adult stem cells. Gradually, when the repair process is completed, the involution of blood vessels occurs, and scar tissue will be formed without having a major effect on the integrity of retinal layers.

Immunosenescence

A possible reason for the dysfunctional immune system in AMD could be immunosenescence, i.e., the aged and exhausted local immune cells in the retina that are unable to communicate with the systemic immune system. Immunosenescence could also play a role in the functional changes arising in T cell-mediated pathways. For example, CD28 receptor activation stimulates T cells to produce cytokines, chemokines, and signals for their expansion as well as their differentiation [44]. T cells start losing the expression of CD28 with age, leading to a reduced overall immune response and this is also found to have an association with AMD [45].
T cells isolated from AMD patients showed a higher expression of the immunosenescent marker CD56 and loss of the CD28 receptor, indicating a reduced protective T cell response [46][47]. The over-expression of immunosenescent markers could generate functional differences in the normal state as well, for example, changes in the expression of the programmed cell death protein-1 (PD-1) and T cell immunoglobulin domain 3 (TIM-3) markers are associated with T cell exhaustion, and regulating these markers has been found to restore T cell effector function [48]. Cross-recognition of antigens by receptors is also a factor in the T cell functional difference, as it could replace the required response. However, senescence is inevitable for T cells, like all aging cells, so cellular irregularities associated with aging can be a result of failure of the endogenous repair process, as well as due to cellular susceptibility to disease or pathologic condition.
A well-orchestrated, adequately replenished inflammatory response is required in such a pathological scenario to deliver protection from further damage and to ensure that functionality and structure are restored in the affected tissues [40]. When the exhausted immune cells and overwhelmed local reparative functions that occur in AMD fail to mediate a successful controlled inflammatory response, this culminates in advancing stages of AMD and progressive loss of vision [49][50].
The loss of effector function, immunological tolerance, and antigen-specific immunosuppressive functions of T cells contribute to the progression of neurodegenerative diseases like AMD. It is not just single factor/receptor/cytokine dysregulation that is involved in the disease etiology, but multifactorial events, implicating an exhausted immune system as a result of aging. Indeed, T cells are required for disease modification, but again the context is important [51]. Context determines whether T cells initiate physiological or pathological responses, and appropriate T cell subsets are required to orchestrate the processes of tissue repair and regeneration that determine disease progression. A further important factor to be considered is whether the immune pathology is the key factor in determining the progression of a disease like AMD, or whether it is the decrease in the abnormal deposits (drusen) that are required for disease modification.

3. The Concept of Autoimmunity in AMD

Autoimmunity is defined as a response of the immune system that is mounted against its own/host cells, tissues, proteins, or other normal components of the body. These ‘self-proteins’ or ‘autoantigens’ are recognized by antibodies (autoantibodies) that orchestrate a response to maintain homeostasis at the site of antigen release. Under normal circumstances, autoantibodies are generated in order to destroy cancerous cells, cells infected by microorganisms, injured cells, cells that are dying, or for a specific purpose, that needs further investigation. The reactivity of these autoantibodies is highly dependent on the microenvironment, disease conditions, and the genetic traits of the individual [52].
The autoimmunity associated with a break in anergy/tolerance, in other words in a system that has ‘gone out of control’, induces the possibility of detrimental autoreactive T cell expansion [53]. Autoreactive T cells are normally beneficial when activated through antigen presentation or through growth factor-expressing resident microglia in the CNS [54]. Sometimes, an immune response may contribute to an ongoing pathology by being reactive against self-proteins and cells, inducing inflammatory responses that can have collateral damage to neighboring tissues [55]. While this may be an attempt to aid recovery, a badly timed intervention or an inadequate response may fail to generate the required cell activity (phenotype) [55]. Another possible scenario is the transition of inflammation and immune responses to the later stages of repair with incomplete cellular responses in the initial stages. What is necessary in AMD is an immune response towards the RPE that will facilitate repair in the initial stages of injury. If this does not happen successfully, a recurring immune activity occurs at the site (RPE) and the insult persists. This continuous process of unsuccessful recovery by the immune system weakens the efficiency of RPE in carrying out normal functions like eliminating the metabolic waste, resulting in the formation of debris within the RPE–BM–choroid interface [28][56][57].
Now, despite the pre-existing immune activity to repair retinal damage, these debris generate another set of immune responses designed to prevent them from accumulating or acting as antigenic stimuli. These are, in turn, self-reactive responses when taken over by antigen-presenting cells (APCs), as they break down the peptides in drusen and present them to T cells. These peptides can be perceived as a threat to the eye by the immune system that can then mount a response for clearing them through an antibody response to these proteins, and thus collateral damage is initiated. As a result, the escalating immune response affects normal retinal functioning, where damage may happen to essential proteins, exacerbating the damage in the RPE [58].
The presence of autoantigens and autoantibodies in aging and in AMD eyes is reported in several scientific studies [9][59][60][61][62][63][64][65][66][67][68][69][70]. Although these studies report the involvement of autoantigens and autoantibodies in both conditions, the exact mechanism of their origin and their role in disease pathogenesis is unclear, even after many years of research [52][59]. In AMD, the existing inflammatory response might not be sufficient to attenuate the ongoing pathology, resulting in a compromise of the repair function of RPE cells. The release of autoantigens by the retina in AMD is initiated to facilitate repair by inducing more inflammation and immune cell recruitment to the damage site. Under normal physiology, the autoantigens are necessary for retinal functioning. In disease, these autoantigens might be released due to the breakdown of homeostasis in the retina in order to enhance autoreactivity (Table 1). However, this controlled and beneficial autoimmune response can sometimes become detrimental, based on the nature of the disease and whether the response intensity and timing are suitably regulated [54].
Table 1. The autoantigens associated with age-related macular degeneration.
No Autoantigens in AMD References
1 Cardiolipin [70]
2 Retinol binding protein (RBP3) [9]
3 Aldolase C (ALDOC), [9]
4 Retinaldehyde binding protein 1 (RLBP1) [9]
5 Pyruvate kinase isozyme M2 (PKM2) [9]
6 Carboxyethyl pyrrole (CEP) [63]
7 Annexin A5 [62]
8 HSPA8 [62]
9 HSPA9 [62]
10 HSPB4/CRYAA (Alpha-A Crystallin) [62]
11 Protein S100-A9/calgranulin B [62]
12 Alpha-enolase [68]
13 Alpha-crystallin [68][69]
14 Glial fibrillary acidic protein (GFAP) [68]
15 CD5L/Apoptosis Inhibitor of macrophage (AIM) [64]
Figure 2 illustrates that in AMD, already exhausted immune cells presenting the retinal self-antigen might generate a locally harmful rather than a favorable immune response. When these same antigens are presented in peripheral tissues away from the chronic inflammatory site (the AMD eye), a beneficial immune response ensues so that naïve T cells are activated by the APCs. It is noted that the context of the peripheral antigen presentation is a big factor, as this could influence the risk of autoimmune inflammation [51]. Therefore, in the case of AMD, a well-controlled robust peripheral immune response is vital and enables the recruitment of fresh immune cells to the site of injury/ocular-immune crosstalk that can alter the ongoing pathology. It is suggested that the presentation of autoantigens in the periphery in the form of a vaccine to induce such a beneficial immune response could be of therapeutic benefit (Figure 2).
Life 13 02236 g002
Figure 2. Hypothetical diagrammatic representation of the effects of autoantigen when presented in the AMD eye versus peripheral tissues. (A) The local delivery of autoantigens in retina is not able to produce a beneficial response by recruiting immune cells to the site (numbers 1–6 explains the sequence of mechanisms when autoantigen is delivered in the AMD eye). (B) The peripheral tissue delivery of autoantigens evokes a local beneficial response resulting in recruitment of immune cells to the retina mediated by T cells (numbers 1–6 explains the sequence of mechanisms when autoantigen is delivered in the peripheral tissues) APCs: antigen presenting cells; MHC: major histocompatibility complex; Ap: antigen presentation; RPE: retinal pigment epithelium; LOP: loss of photoreceptors; CNV: choroidal neovascularization; arrow: blue represents the peripheral route, and red represents the local ocular route.

Therapeutic Delivery of Autoantigens

Autoantigen delivery via a site away from injury in age-related neurodegenerative chronic inflammatory disease (ANCID) may be better than one close to the site of injury, both in terms of feasibility and to achieve a better immune response in ANCID like wAMD. There are number of advantages exploiting the peripheral route rather than the intravitreal route (Figure 3).
Life 13 02236 g003
Figure 3. Advantages of peripheral route over intravitreal injection for delivery of drugs. Image created in Biorender.com [71][72][73].
Antigens are foreign substances that induce an immune response. As they enter our body, immune cells recognize and process them to generate an effective combative response in order to maintain a safe environment for the host. If autoantigens are delivered to peripheral tissues away from the retina and choroid, this increases the possibility of inducing a beneficial immune response that would be absent if autoantigens were delivered to the retina under hostile conditions. The peripheral response could be therapeutic, as it will bring an improved immune balance by recruiting cells from the systemic circulation to the local site of damage (retina) to assist in modifying the ongoing local neurodegenerative situation. A similar approach taken in a previous study has shown that the balance of local versus peripheral immune responses might not be beneficial in every individual, but the benefit can be acquired by boosting/harnessing the response of the systemic immune system [54][74][75]. Bakalash et al. (2005) [74] reported that a similar peripherally mediated process led to the homing of T cells to the eye, and a neuroprotective effect mediated by these recruited T cells was observed in rat models with chronically high intraocular pressure. The above indicates that a boost of the peripheral immune cells may elicit a systemic T cell-mediated response that is beneficial for the repair activity of damaged RPE cells. Table 1 shows the list of autoantigens that have been found from human AMD samples. It is not certain whether all autoantigen peptides can induce a protective effect [54]. A further study might be required to see how immune cells select particular proteins for antigen presentation to elicit protective autoreactive immunity through adaptive immune cells.

This entry is adapted from the peer-reviewed paper 10.3390/life13122236

References

  1. Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.G.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health 2014, 2, E106–E116.
  2. WHO. World Report on Vision; WHO: Geneva, Switzerland, 2019.
  3. Hernández-Zimbrón, L.F.; Zamora-Alvarado, R.; La Paz, L.O.-D.; Velez-Montoya, R.; Zenteno, E.; Gulias-Cañizo, R.; Quiroz-Mercado, H.; Gonzalez-Salinas, R. Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD. Oxid. Med. Cell. Longev. 2018, 2018, 8374647.
  4. Augustin, A.J.; Kirchhof, J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin. Ther. Targets 2009, 13, 641–651.
  5. Gu, X.; Neric, N.J.; Crabb, J.S.; Crabb, J.W.; Bhattacharya, S.K.; Rayborn, M.E.; Hollyfield, J.G.; Bonilha, V.L. Age-related changes in the retinal pigment epithelium (RPE). PLoS ONE 2012, 7, e38673.
  6. Frank, R.N.; Puklin, J.E.; Stock, C.; Canter, L.A. Race, iris color and age-related macular degeneration. Trans. Am. Ophthalmol. Soc. 2000, 98, 109–115.
  7. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000, 107, 2224–2232.
  8. Nussenblatt, R.B.; Lee, R.W.J.; Chew, E.; Wei, L.; Liu, B.; Sen, H.N.; Dick, A.D.; Ferris, F.L. Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. Am. J. Ophthalmol. 2014, 158, 5–11.e2.
  9. Morohoshi, K.; Ohbayashi, M.; Patel, N.; Chong, V.; Bird, A.C.; Ono, S.J. Identification of anti-retinal antibodies in patients with age-related macular degeneration. Exp. Mol. Pathol. 2012, 93, 193–199.
  10. Bonilha, V. Age and disease-related structural changes in the retinal pigment epithelium. Clin. Ophthalmol. 2008, 2, 413–424.
  11. Chirco, K.R.; Sohn, E.H.; Stone, E.M.; Tucker, B.A.; Mullins, R.F. Structural and molecular changes in the aging choroid: Implications for age-related macular degeneration. Eye 2017, 31, 10–25.
  12. Hageman, D.A.G.S.; Gehrs, K.; Johnson, L.V. Age-related macular degeneration (AMD). Organ. Retin. Vis. Syst. 2009, 66, 1–44.
  13. Kauppinen, A.; Kaarniranta, K.; Salminen, A. Potential Role of Myeloid-Derived Suppressor Cells (MDSCs) in Age-Related Macular Degeneration (AMD). Front. Immunol. 2020, 11, 1–12.
  14. Philippidis, A. StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy. Genet. Eng. Biotechnol. News 2023, 5, 186–191.
  15. Borchert, G.A.; Shamsnajafabadi, H.; Hu, M.L.; De Silva, S.R.; Downes, S.M.; MacLaren, R.E.; Xue, K.; Cehajic-Kapetanovic, J. The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy. Cells 2023, 12, 2092.
  16. Khan, M.; Aziz, A.A.; Shafi, N.A.; Abbas, T.; Khanani, A.M. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells 2020, 9, 1869.
  17. Hussain, R.M.; Shaukat, B.A.; Ciulla, L.M.; Berrocal, A.M.; Sridhar, J. Vascular endothelial growth factor antagonists: Promising players in the treatment of neovascular age-related macular degeneration. Drug Des. Dev. Ther. 2021, 15, 2653–2665.
  18. Liberski, S.; Wichrowska, M.; Kocięcki, J. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int. J. Mol. Sci. 2022, 23, 9424.
  19. Shirley, M. Faricimab: First Approval. Drugs 2022, 82, 825–830.
  20. Song, D.; Liu, P.; Shang, K.; Ma, Y.B. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front. Bioeng. Biotechnol. 2022, 10, 943915.
  21. Van Bergen, T.; Etienne, I.; Cunningham, F.; Moons, L.; Schlingemann, R.O.; Feyen, J.H.M.; Stitt, A.W. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog. Retin. Eye Res. 2019, 69, 116–136.
  22. Nair, A.A.; Finn, A.P.; Sternberg, P. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy. Drug Des. Dev. Ther. 2022, 16, 3395–3400.
  23. Tan, W.; Zou, J.; Yoshida, S.; Jiang, B.; Zhou, Y. The role of inflammation in age-related macular degeneration. Int. J. Biol. Sci. 2020, 16, 2989–3001.
  24. Agarwal, M.; Majumder, P.D.; Babu, K.; Konana, V.; Goyal, M.; Touhami, S.; Stanescu-Segall, D.; Bodaghi, B. Drug-induced uveitis: A review. Indian J. Ophthalmol. 2020, 68, 1799–1807.
  25. Winkler, T.W.; Grassmann, F.; Brandl, C.; Kiel, C.; Günther, F.; Strunz, T.; Weidner, L.; Zimmermann, M.E.; Korb, C.A.; Poplawski, A.; et al. Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. BMC Med. Genom. 2020, 13, 120.
  26. Anderson, D.H.; Radeke, M.J.; Gallo, N.B.; Chapin, E.A.; Johnson, P.T.; Curletti, C.R.; Hancox, L.S.; Hu, J.; Ebright, J.N.; Malek, G.; et al. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog. Retin. Eye Res. 2010, 29, 95–112.
  27. Bradley, D.T.; Zipfel, P.F.; Hughes, A.E. Complement in age-related macular degeneration: A focus on function. Eye 2011, 25, 683–693.
  28. Detrick, B.; Hooks, J.J. The RPE Cell and the Immune System. In Retinal Pigment Epithelium in Health and Disease; Springer: Cham, Switzerland, 2020.
  29. Kauppinen, A.; Paterno, J.J.; Blasiak, J.; Salminen, A.; Kaarniranta, K. Inflammation and its role in age-related macular degeneration. Cell. Mol. Life Sci. 2016, 73, 1765–1786.
  30. Schwartz, M.; Shechter, R. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 2010, 6, 405–410.
  31. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428–435.
  32. Chen, M.; Xu, H. Parainflammation, chronic inflammation, and age-related macular degeneration. J. Leukoc. Biol. 2015, 98, 713–725.
  33. Nathan, C. Points of control in inflammation. Nature 2002, 420, 846–852.
  34. Nathan, C.; Ding, A. Nonresolving Inflammation. Cell 2010, 140, 871–882.
  35. Telander, D.G. Inflammation and age-related macular degeneration (AMD). Semin. Ophthalmol. 2011, 26, 192–197.
  36. Osuka, A.; Ogura, H.; Ueyama, M.; Shimazu, T.; Lederer, J.A. Immune response to traumatic injury: harmony and discordance of immune system homeostasis. Acute Med. Surg. 2014, 1, 63–69.
  37. Lazzara, F.; Conti, F.; Platania, C.B.M.; Eandi, C.M.; Drago, F.; Bucolo, C. Effects of Vitamin D3 and Meso-Zeaxanthin on Human Retinal Pigmented Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related Macular Degeneration. Front. Pharmacol. 2021, 12, 778165.
  38. Chen, M.; Luo, C.; Zhao, J.; Devarajan, G.; Xu, H. Immune regulation in the aging retina. Prog. Retin. Eye Res. 2019, 69, 159–172.
  39. Ma, W.; Zhang, Y.; Gao, C.; Fariss, R.N.; Tam, J.; Wong, W.T. Monocyte infiltration and proliferation reestablish myeloid cell homeostasis in the mouse retina following retinal pigment epithelial cell injury. Sci. Rep. 2017, 7, 8433.
  40. Schwartz, M.; Baruch, K. The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J. 2014, 33, 7–22.
  41. Schwartz, M.; Raposo, C. Protective autoimmunity: A unifying model for the immune network involved in CNS repair. Neuroscientist 2014, 20, 343–358.
  42. Kent, D.; Sheridan, C. Choroidal neovascularization: A wound healing perspective. Mol. Vis. 2003, 9, 747–755.
  43. Kent, D.L. Age-related macular degeneration: Beyond anti-angiogenesis. Mol. Vis. 2014, 20, 46–55.
  44. Hünig, T.; Beyersdorf, N.; Kerkau, T. CD28 co-stimulation in T-cell homeostasis: A recent perspective. Immunotargets Ther. 2015, 2015, 111–122.
  45. Madelung, C.F.; Falk, M.K.; Sørensen, T.L. The association between neovascular age-related macular degeneration and regulatory T cells in peripheral blood. Clin. Ophthalmol. 2015, 9, 1147–1154.
  46. Faber, C.; Singh, A.; Falk, M.K.; Juel, H.B.; Sørensen, T.L.; Nissen, M.H. Age-related macular degeneration is associated with increased proportion of CD56+ T cells in peripheral blood. Ophthalmology 2013, 120, 2310–2316.
  47. Behnke, V.; Wolf, A.; Langmann, T. The role of lymphocytes and phagocytes in age-related macular degeneration (AMD). Cell. Mol. Life Sci. 2020, 77, 781–788.
  48. Boldison, J.; Chu, C.J.; Copland, D.A.; Lait, P.J.P.; Khera, T.K.; Dick, A.D.; Nicholson, L.B. Tissue-Resident Exhausted Effector Memory CD8 + T Cells Accumulate in the Retina during Chronic Experimental Autoimmune Uveoretinitis. J. Immunol. 2014, 192, 4541–4550.
  49. Ambati, J.; Atkinson, J.P.; Gelfand, B.D. Immunology of age-related macular degeneration. Nat. Rev. Immunol. 2013, 13, 438–451.
  50. Ascunce, K.; Dhodapkar, R.M.; Huang, D.; Hafler, B.P. Innate immune biology in age-related macular degeneration. Front. Cell Dev. Biol. 2023, 11, 1118524.
  51. Voigt, V.; Wikstrom, M.E.; Kezic, J.M.; Schuster, I.S.; Fleming, P.; Makinen, K.; Daley, S.R.; Andoniou, C.E.; Degli-Esposti, M.A.; Forrester, J.V. Ocular antigen does not cause disease unless presented in the context of inflammation. Sci. Rep. 2017, 7, 14226.
  52. Adamus, G. Are anti-retinal autoantibodies a cause or a consequence of retinal degeneration in autoimmune retinopathies. Front. Immunol. 2018, 9, 765.
  53. Toker, A.; Slaney, C.Y.; Bäckström, B.T.; Harper, J.L. Glatiramer acetate treatment directly targets CD11b+Ly6G- monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2011, 74, 235–243.
  54. Butovsky, O.; Koronyo-Hamaoui, M.; Kunis, G.; Ophir, E.; Landa, G.; Cohen, H.; Schwartz, M. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA 2006, 103, 11784–11789.
  55. Avidan, H.; Kipnis, J.; Butovsky, O.; Caspi, R.R.; Schwartz, M. Vaccination with autoantigen protects against aggregated β-amyloid and glutamate toxicity by controlling microglia: Effect of CD4+CD25+ T cells. Eur. J. Immunol. 2004, 34, 3434–3445.
  56. Yang, S.; Zhou, J.; Li, D. Functions and Diseases of the Retinal Pigment Epithelium. Front. Pharmacol. 2021, 12, 727870.
  57. Frederick, P.A.; Kleinman, M.E. The Immune System and AMD. Curr. Ophthalmol. Rep. 2014, 2, 14–19.
  58. Whitcup, S.M.; Sodhi, A.; Atkinson, J.P.; Holers, V.M.; Sinha, D.; Rohrer, B.; Dick, A.D. The role of the immune response in age-related macular degeneration. Int. J. Inflam. 2013, 2013, 348092.
  59. Adamus, G.; Chew, E.Y.; Ferris, F.L.; Klein, M.L. Prevalence of anti-retinal autoantibodies in different stages of Age-related macular degeneration. BMC Ophthalmol. 2014, 14, 1–9.
  60. Patel, N.; Ohbayashi, M.; Nugent, A.K.; Ramchand, K.; Toda, M.; Chau, K.Y.; Bunce, C.; Webster, A.; Bird, A.C.; Ono, S.J.; et al. Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology. 2005, 115, 422–430.
  61. Morohoshi, K.; Patel, N.; Ohbayashi, M.; Chong, V.; Grossniklaus, H.E.; Bird, A.C.; Ono, S.J. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization. Exp. Mol. Pathol. 2012, 92, 64–73.
  62. Iannaccone, A.; Giorgianni, F.; New, D.D.; Hollingsworth, T.J.; Umfress, A.; Alhatem, A.H.; Neeli, I.; Lenchik, N.I.; Jennings, B.J.; Calzada, J.I.; et al. Circulating autoantibodies in age-related macular degeneration recognize human macular tissue antigens implicated in autophagy, immunomodulation, and protection from oxidative stress and apoptosis. PLoS ONE 2015, 10, 1–22.
  63. Gu, X.; Meer, S.G.; Miyagi, M.; Rayborn, M.E.; Hollyfield, J.G.; Crabb, J.W.; Salomon, R.G. Carboxyethylpyrrole Protein Adducts and Autoantibodies, Biomarkers for Age-related Macular Degeneration. J. Biol. Chem. 2003, 278, 42027–42035.
  64. Iannaccone, A.; Hollingsworth, T.J.; Koirala, D.; New, D.D.; Lenchik, N.I.; Beranova-Giorgianni, S.; Gerling, I.C.; Radic, M.Z.; Giorgianni, F. Retinal pigment epithelium and microglia express the CD5 antigen-like protein, a novel autoantigen in age-related macular degeneration. Exp. Eye Res. 2017, 155, 64–74.
  65. Umeda, S.; Suzuki, M.T.; Okamoto, H.; Ono, F.; Mizota, A.; Terao, K.; Yoshikawa, Y.; Tanaka, Y.; Iwata, T. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J. 2005, 19, 1581–1760.
  66. Morohoshi, K.; Goodwin, A.M.; Ohbayashi, M.; Ono, S.J. Autoimmunity in retinal degeneration: Autoimmune retinopathy and age-related macular degeneration. J. Autoimmun. 2009, 33, 247–254.
  67. Kubicka-Trzäska, A.; Wilańska, J.; Romanowska-Dixon, B.; Sanak, M. Circulating antiretinal antibodies predict the outcome of anti-VEGF therapy in patients with exudative age-related macular degeneration. Acta Ophthalmol. 2012, 90, e21–e24.
  68. Joachim, S.C.; Bruns, K.; Lackner, K.J.; Pfeiffer, N.; Grus, F.H. Analysis of IgG antibody patterns against retinal antigens and antibodies to α-crystallin, GFAP, and α-enolase in sera of patients with “wet” age-related macular degeneration. Graefe Arch. Clin. Exp. Ophthalmol. 2007, 245, 619.
  69. Nakata, K.; Crabb, J.W.; Hollyfield, J.G. Crystallin distribution in Bruch’s membrane-choroid complex from AMD and age-matched donor eyes. Exp. Eye Res. 2005, 80, 821–826.
  70. Özkan, B.; Karabaş, L.V.; Altintaş, Ö.; Tamer, G.S.; Yüksel, N.; Ça, Y. Plasma antiphospholipid antibody levels in age-related macular degeneration. Can. J. Ophthalmol. 2012, 47, 264–268.
  71. Patel, P.B.; Shastri, D.H.; Shelat, P.K.; Shukla, A.K. Ophthalmic drug delivery system: Challenges and approaches. Syst. Rev. Pharm. 2010, 1, 113.
  72. Melo, G.B.; da Cruz, N.F.S.; Emerson, G.G.; Rezende, F.A.; Meyer, C.H.; Uchiyama, S.; Carpenter, J.; Shiroma, H.F.; Farah, M.E.; Maia, M.; et al. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog. Retin. Eye Res. 2021, 80, 100862.
  73. Falavarjani, K.G.; Nguyen, Q.D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye 2013, 27, 787–794.
  74. Bakalash, S.; Shlomo, G.B.; Aloni, E.; Shaked, I.; Wheeler, L.; Ofri, R.; Schwartz, M. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J. Mol. Med. 2005, 83, 904–916.
  75. Belokopytov, M.; Ben-Shlomo, G.; Rosner, M.; Belkin, M.; Dubinski, G.; Epstein, Y.; Ofri, R. Functional efficacy of glatiramer acetate treatment for laser-induced retinal damage in rats. Lasers Surg. Med. 2008, 40, 196–201.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback